Tasigna Class Action Lawsuit | Get the Right Lawyer

Our team of attorneys specializing in class actions is initiating legal suits on behalf of individuals harmed by Tasigna (nilotinib), an anti-cancer drug associated with a significant adverse effect known as atherosclerosis, a condition characterized by the accumulation of plaque within the arteries.

Free Confidential Lawsuit Evaluation: If you or a loved one was injured by the side effects of Tasigna, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit against the manufacturer and we can help.

What’s the problem?

Manufactured and marketed by Novartis International AG, Tasigna (generic: nilotinib) is currently one of the most profitable drugs in the world, with nearly $2 billion in sales in 2016 alone. Prescribed to treat a type of blood cancer known as chronic myeloid leukemia (CML), Tasigna has been found to cause severe and rapid-onset atherosclerosis, a life-threatening cardiovascular disease characterized by a thickening of the arterial walls.

Read more: Tasigna chemotherapy drug recall lawsuit

Tasigna Side Effects

• Atherosclerosis
• Peripheral artery disease (PAD)
• Coronary artery disease (CAD)
• Carotid artery disease
• Hardening / narrowing of the peripheral arteries
• Heart attack
• Stroke
• Angina
• Other arterial diseases
• Limb amputations
• Blood disorders
• Blood clots
• Death
• And more

Important Information for Patients with Heart Problems

As we’ve learned by this point in the article, Tasigna may increase the risk of severe heart problems, especially when taken in conjunction with other medicines. Talk to your doctor about all the drugs you take before deciding whether to take Tasigna. Your heart function may need to be checked before and during treatment if you decide in favor of a regimen.

Can I Participate in a Class Action?

The law offices of Schmidt & Clark, LLP, have decided not to file a personal injury class action lawsuit over Tasigna, and are instead only filing individual claims on behalf of injured parties. We believe this decision is in the best interest of our clients, as class actions in defective drug litigation often result in “low-ball” settlement agreements and high attorney fees. If you’ve been injured, contact us today to learn more about your legal rights.

FAQs

How do class action lawsuits differ from individual lawsuits for Tasigna claims?

Class action lawsuits involve a group of plaintiffs with similar claims against a defendant, streamlining the legal process and pooling resources. Individual lawsuits allow plaintiffs to pursue their unique claims separately, potentially leading to higher individual settlements or verdicts.

What are the benefits of joining a Tasigna class action lawsuit?

Benefits include shared legal costs, strength in numbers, and a streamlined process. Class action lawsuits can also raise public awareness and put pressure on the defendant for a settlement.

What should I expect during the legal process of a Tasigna class action lawsuit?

Expect to go through stages such as filing the complaint, discovery (exchange of evidence), pre-trial motions, potential settlement negotiations, and possibly a trial. The process can take several months to years.

Can family members join the Tasigna class action lawsuit if a loved one has died from related side effects?

Yes, family members can join the lawsuit on behalf of a deceased loved one. They may be eligible to file a wrongful death claim as part of the class action.

See all dangerous pharmaceutical torts we’ve taken on.

Do I have a Tasigna Lawsuit?

The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Tasigna lawsuits. We are handling individual litigation nationwide and currently accepting new atherosclerosis cases in all 50 states.

Free Case Evaluation: Again, if you were harmed by Tasigna side effects, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.